These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33882758)

  • 1. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease.
    Lamos EM; Kristan M; Siamashvili M; Davis SN
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):837-852. PubMed ID: 33882758
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-diabetic drugs and NASH: from current options to promising perspectives.
    Smati S; Canivet CM; Boursier J; Cariou B
    Expert Opin Investig Drugs; 2021 Aug; 30(8):813-825. PubMed ID: 34214406
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.
    Tang W; Xu Q; Hong T; Tong G; Feng W; Shen S; Bi Y; Zhu D
    Diabetes Metab Res Rev; 2016 Feb; 32(2):200-16. PubMed ID: 26381272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.
    Nakouti T; Karagiannis AK; Tziomalos K; Cholongitas E
    Curr Vasc Pharmacol; 2015; 13(5):649-57. PubMed ID: 25412688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
    Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS
    Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
    Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications.
    Scheen AJ
    Diabetes Metab; 2019 Jun; 45(3):213-223. PubMed ID: 30708071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease.
    Raschi E; Mazzotti A; Poluzzi E; De Ponti F; Marchesini G
    Expert Opin Pharmacother; 2018 Dec; 19(17):1903-1914. PubMed ID: 30299993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Carbone LJ; Angus PW; Yeomans ND
    J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice.
    Zhao DM; Li CQ; Sun YM; Fan JY; Wu N; Sun YN; Sun XY
    Endokrynol Pol; 2023; 74(2):190-196. PubMed ID: 37039492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.